Pidu District Yier Commerce and Trade

Retatrutide is an emerging multi-receptor agonist mainly used for the treatment of obesity and metabolic diseases. It is capable of simultaneously activating three incretin receptors, including GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptor. This multiple mechanisms make rotaglutide show great potential for weight management, blood sugar control, and overall metabolic health.